Advertisement
Advertisement
U.S. markets closed
S&P Futures
4,168.00 -23.50 (-0.56%) Dow Futures
34,101.00 +4.00 (+0.01%) Nasdaq Futures
12,640.75 -206.00 (-1.60%) Russell 2000 Futures
2,006.70 -1.20 (-0.06%) Crude Oil
75.91 +0.03 (+0.04%) Gold
1,930.30 -0.50 (-0.03%)
Illumina, Inc. (ILMN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Follow
At close: 04:00PM EST
After hours:
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 216.52 |
| Open | 218.88 |
| Bid | 218.00 x 1100 |
| Ask | 224.10 x 800 |
| Day's Range | 218.37 - 225.38 |
| 52 Week Range | 173.45 - 371.16 |
| Volume | |
| Avg. Volume | 1,209,463 |
| Market Cap | 35.383B |
| Beta (5Y Monthly) | 1.13 |
| PE Ratio (TTM) | 50.66 |
| EPS (TTM) | 4.44 |
| Earnings Date | Feb 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 243.50 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-1% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for ILMN
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Illumina, Inc.Analyst Report: Illumina IncIllumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic analysis. The company's products and services are sold to genomic research centers, academic institutions, government and commercial laboratories, and hospitals, as well as to pharmaceutical, biotech, agrigenomics, and consumer genomics businesses. The company's portfolio of products and services are designed to accelerate and simplify genetic analysis. The company also invests in startup companies that are pursuing promising genomic-related opportunities. It has roughly 9,800 full-time employees. ILMN shares are included in the S&P 500 index.RatingFair ValueEconomic Moat9 days agoArgus Research
- Zacks
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy?
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- ACCESSWIRE
Illumina Named to Bloomberg Gender Equality Index for Fifth Consecutive Year
Illumina has been included in the 2023 Bloomberg Gender-Equality Index for the fifth consecutive year.
- Insider Monkey
Top 25 Smartest Companies To Buy According To Hedge Funds
In this piece, we will take a look at the top 25 smartest companies to buy according to hedge funds. For more companies, head on over to Top 5 Smartest Companies To Buy According To Hedge Funds. Surviving in the modern day corporate world is not for the faint of heart. Business is a ruthless […]
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2023 Yahoo. All rights reserved.
